Project Grant HT9425261E158
Award Date 6/1/26
Completion Date 5/31/29
Dollars Obligated $1.7M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90024, USA
Similar Awards
- Federal Grant Award Summary UCLA has received a $2.08M Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective September 1, 2026 through August 31, 2030. The grant supports research to define an error-free DNA repair signature as a predictive marker for lethal prostate cancer. This research initiative contributes to the DHA's broader mission of advancing biomedical innovation to transform healthcare for military...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded University of California, Los Angeles (UCLA) a $799,999 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective May 1, 2026, with a completion date of April 30, 2030. The project, titled "From H & E to HRD: Linking Morphometry, Clinical, and Molecular Data for Drug Response Prediction," will be conducted at UCLA's Los Angeles campus through the Office of Research...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded a $235,476 project grant to the University of California, Los Angeles (UCLA) Office of Research Administration on November 1, 2025, to develop new cell-mediated immunotherapeutic strategies for neuroendocrine prostate cancer. The two-year award, which concludes October 31, 2027, is funded under the Military Medical Research and Development program (CFDA 12.420) and will be conducted at UCLA's Los Angeles, California facility....
- The University of California, Los Angeles (UCLA) has been awarded a $626,081 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program, administered by the Defense Health Agency. The grant, titled "Combinatorial Phenotype-Targeted Therapy to Overcome Mechanisms Driving Prostate Cancer Treatment Resistance," will support advanced biomedical research to transform healthcare for military service members and the broader public. The research...
- Federal Grant Award Summary The University of California, Los Angeles (UCLA) received a $551,216 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective August 1, 2025, through July 31, 2027. The grant funds research to elucidate the functional role of PPP1R1B-lncRNA in myocyte repair in Duchenne muscular dystrophy (DMD). This research initiative represents a hypothesis-driven investigation into therapeutic...
- This federal Project Grant award, valued at $2,520,000.00, was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. The primary awardee, the University of California, Los Angeles (UCLA), will leverage its extensive facilities, diverse faculty expertise, and robust administrative capabilities...
- Federal Project Grant Award Summary The Defense Health Agency (DHA) awarded the University of California, Los Angeles (UCLA) a $590,625 project grant effective September 1, 2025, through August 31, 2028, under the Military Medical Research and Development program (CFDA 12.420). The grant funds a pilot study investigating dual immunotherapy targeting PD-1 (programmed death receptor 1) and CD73 in combination with chemotherapy for patients with pancreatic adenocarcinoma, with specific focus on...
- Federal Grant Award Summary The Defense Health Agency (DHA) awarded University of California, Los Angeles (UCLA) a $590,625 Project Grant under the Military Medical Research and Development program (CFDA 12.420) effective September 1, 2025, through August 31, 2028. UCLA will conduct a pilot study investigating dual immunotherapy targeting PD-1 (programmed death receptor 1) and CD73 in combination with chemotherapy for patients with pancreatic adenocarcinoma, with a focus on identifying immune...
- The University of California, Los Angeles (UCLA), through its Office of Research Administration, was awarded a $1,366,628 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research into the role of oxidative mitochondrial metabolism in resistance to androgen receptor inhibition from July 1, 2023 to June 30, 2026. As the prime awardee, UCLA will leverage its research facilities and faculty...
- The University of California, Los Angeles (UCLA), under its Office of Research Administration, received a $157,473 Project Grant award from the Defense Health Agency (DHA) on May 1, 2024 to conduct research for the "TESTING UCHL1 AS A NEW MINIMALLY INVASIVE BIOMARKER AND THERAPEUTIC TARGET FOR NEUROENDOCRINE PROSTATE CANCER" project. This award is funded through the DHA's Military Medical Research and Development program (CFDA 12.420), which supports a range of biomedical research...